Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Receivables (2024 - 2025)

Prime Medicine (PRME) has disclosed Receivables for 2 consecutive years, with $4.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables rose 185.02% year-over-year to $4.6 million, compared with a TTM value of $4.6 million through Dec 2025, up 185.02%, and an annual FY2025 reading of $4.6 million, up 185.02% over the prior year.
  • Receivables was $4.6 million for Q4 2025 at Prime Medicine, up from $120000.0 in the prior quarter.
  • Across five years, Receivables topped out at $55.0 million in Q3 2024 and bottomed at $17000.0 in Q1 2025.